AstraZeneca Needs New Breast Cancer Drug to be Blockbuster
The company had to go to the public market to help finance its $7 billion in the Daiichi Sankyo treatmentRelated Stocks: AZN, RHHBF, NVS, PFE, PBYI, MGNX,.....»»
AstraZeneca Shares Trade Higher After FDA Grants Breast Cancer Drug Priority Review
AstraZeneca plc (NYSE: AZN) and partner DAIICHI SANKYO/S ADR (OTC: DSNKY) announced positive news Thursday on their HER-2 targeting antibody drug conjugate, or ADC. read more.....»»
AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche......»»
Pfizer sales miss as breast cancer drug disappoints
(Reuters) - Leading U.S. drugmaker Pfizer Inc racked up its biggest miss on sales in a year in the first quarter, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz......»»
AstraZeneca to present update on ph3 trial of LYNPARZA in early breast cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
AstraZeneca to withdraw drug used to treat bladder cancer
Shares of AstraZeneca were down 0.1% in trading on Monday after the drugmaker said it voluntarily withdrew an indication grant.....»»
AstraZeneca/Merck"s PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis
read more.....»»
AstraZeneca"s Enhertu approved in EU for HER2-positive metastatic breast cancer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Immunomedics in spotlight following accelerated approval for breast cancer drug
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug
Shares of Immunomedics Inc. gained 1% in trading on Wednesday after the Food and Drug Adminstration (FDA) .....»»
FDA grants approval for new drug to treat aggressive breast cancer
The FDA has granted accelerated approval to Immunomedics for a drug used to treat a severe type of breast cancer......»»
FDA approves Immunomedics breast cancer drug with boxed warning
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Seattle Genetics" stock rises on early FDA nod for breast-cancer drug
Shares of Seattle Genetics Inc. gained 1.0% in trading on Friday after the Food and Drug Administration approved Tukysa for certain patients with HER2-positive breast cancer when given in combination with chemotherapy. The drug has a wholesale.....»»
AstraZeneca to test blood-cancer drug for severely ill COVID-19 patients
Shares of AstraZeneca were up 0.6% in trading on Tuesday; this morning the .....»»
AstraZeneca shares surge on Phase 3 trial success of lung cancer drug
Shares of AstraZeneca.....»»
AstraZeneca"s cancer drug sees early unblinding in key trial, Reuters reports
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Says In Double Downgrade
Immunomedics, Inc. (NASDAQ: IMMU) is knocking the FDA door a second time for its lead drug sacituzumab govitecan in triple-negative breast cancer. Lat.....»»
Pfizer profit misses as breast cancer drug sales fall short of estimates
Pfizer Inc posted a quarterly profit on Tuesday that came in below Wall Street estimates, as sales of breast cancer drug Ibrance fell short of expectations......»»
Johnson & Johnson misses revenue estimates as blockbuster drugs disappoint
Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»
J&J misses revenue estimates as blockbuster drugs disappoint
Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations......»»
Dow Jones Newswires: AstraZeneca: FDA gives orphan drug status to two liver cancer drugs
Imfinzi and tremelimumab were given orphan drug status as treatments for hepatocellular carcinoma, or HCC......»»